Abstract. Vascular endothelial growth factor and its tyrosine kinase receptors have been identified as key mediators of the regulation of pathologic blood vessel growth and maintenance in the promotion of angiogenesis and tumor growth. Therefore, an alternative approach to destroying tumor endothelium would be to make this tissue particularly sensitive to VEGF-mediated drug delivery. To verify this hypothesis, we generated a protein containing VEGF 165 fused to melittin. Melittin is a small linear peptide composed of 26 amino acid residues that can exert toxic or inhibitory effects on many types of tumor cells. This protein is a cytolytic peptide that attacks lipid membranes, leading to significant toxicity. In the present study, the Pichia pastoris expression system was used to express the fusion protein. Under optimal conditions, stable VEGF 165 -melittin production was achieved using a series of purification steps. The activity of VEGF 165 -melittin fusion protein was compared with melittin for its ability to suppress the growth of tumor cell line in vitro. The fusion toxin selectively inhibited growth of human hepatocellular carcinoma HepG-2 cell line with high expression of VEGFR-2. We found that sensitivity of VEGFR-2 transfected 293 cells to VEGF 165 -melittin enhanced as the cellular VEGFR-2 density increased. In an in vivo initial experiment, the fusion protein inhibited tumor growth in xenografts assays. Furthermore, successful expression and characterization of the fusion protein demonstrated its efficacy for use as a novel treatment strategy for cancer.
Introduction
The growth and metastatic spread of malignant tumors cannot proceed without the development of a vascular supply. Vascular endothelial growth factor-A (VEGF-A) plays a key role in tumor angiogenesis (1) (2) (3) (4) . The significant amount of VEGFR expression in the tumor vasculature presents a unique opportunity for therapeutic intervention. VEGF and its receptor VEGFR-1/VEGFR-2 provide an alternative approach for destroying tumor endothelium through targeting in combination with agents that kill cells, making them targets for the delivery of potent toxins to tumor endothelial cells (5, 6) . VEGF mRNA is alternatively spliced, leading to proteins that are 208, 189, 165, or 121 amino acids in length (7) . VEGF 165 and VEGF 121 are secreted as soluble factors; however, VEGF 208 and VEGF 189 are secreted while binding to the extracellular matrix (8) . Compared with VEGF 121 , VEGF 165 retains a heparin-binding domain, which induces binding to the cell surface receptor. Furthermore, VEGF 165 is the most abundantly expressed splice variant (9) . In the present study, we chose melittin for fusion with VEGF. This fusion protein, denoted as VEGFR 165 -melittin, was shown to potently inhibit hepatocellular carcinoma and pancreatic cancer in vivo and in vitro.
Melittin is the principal toxic component in venom from the European honey bee Apis mellifera. This protein is a cationic, hemolytic and small linear peptide composed of 26 amino acid residues. Notably, the N-terminus is predominantly hydrophobic and the C-terminus is hydrophilic. Melittin has various effects, including antibacterial, antiviral, and antiinflammatory effects, in various cell types (10) . It has been reported that melittin can induce apoptosis, cell cycle arrest and growth-inhibition in different tumor cells (11) (12) (13) . However, the significant toxicity of melittin is achieved through a highly non-specific cytolytic attack of lipid membranes (14) . The principle of the melittin toxicity is its physical and chemical destruction of cellular membranes, leading to a profound increase in the cell permeability barrier and leakage of cell contents (15, 16) , thereby precluding any meaningful therapeutic benefit. An alternative approach for achieving practical therapeutic applications would be designing a new paradigm for the targeted delivery of potent toxins to tumor cells. Moreover, it has been reported that melittin suppresses tumor growth by targeting VEGF (17, 18) . Therefore, melittin as a fusion partner should work well with VEGF.
In the present study, we prepared a novel fusion protein, VEGF 165 -melittin, in Pichia pastoris. We generated an effective method for producing the recombinant protein in large quantities with high purity. Our results demonstrate that VEGF 165 -melittin retains functional activities including cytotoxicity and growth inhibition in HepG-2 and MHCC97-H human hepatocellular carcinoma cells in vitro. Furthermore, the fusion toxin was able to inhibit tumor growth in vivo. This fusion protein has the potential to be used as a new paradigm for the targeted delivery of cell-penetrating toxins to kill cancer cells in vitro and in vivo.
Materials and methods
Reagents and materials. Pichia pastoris X-33, the pPICZαC vector, and Zeocin antibiotic were obtained from Invitrogen (Carlsbad, CA, USA). Restriction enzymes, T4 DNA ligase, DNA marker, and the pMD-18T vector were purchased from Takara (Dalian, China). The protein marker was purchased from Thermo Fermentas and New England Biolabs (Guangzhou, China). All primers were synthesized by Shanghai Sangon Biotechnology Corp. (Shanghai, China). Anti-VEGF 165 , anti-VEGFR-1, anti-VEGFR-2, anti-melittin, HRP-goat antirabbit conjugate and HRP-goat anti-mouse conjugate were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Melittin was purchased from Nanning Innovation and Technology Pharmaceutical Co., Ltd. (Guangxi, China). Anti-VEGF blocking antibody was purchased from R&D Systems (Minneapolis, MN, USA). VEGFR-2/KDR gene was purchased from Sino Biological Inc. (Beijing, China).
Human hepatocellular carcinoma cell lines (HepG-2 and MHCC97-H), a human pancreatic adenocarcinoma cell line (AsPC-1), and 293 human primary embryonic kidney cells were obtained from the American Type Culture Collection. All the cells were passaged according to their protocol from ATCC, and no more than 6 months elapsed after the resuscitation and culturing of the cells. Serum and culture medium were purchased from Invitrogen. BALB/c mice and BALB/c nude mice (4-5 weeks) were obtained from the Experimental Animal Research Centre of Zhongshan University and raised in its laboratory. All animal protocols followed the National Guidelines for the Care and Use of Animals.
Yeast culture media. Pichia pastoris was cultured in YPD medium containing 10 g/l yeast extract, 20 g/l peptone and 20 g/l D-glucose. To prepare YPD plates, 2% agar (w/v) was added into YPD medium. YPD-Zeocin plates containing 0.1 mg/ml Zeocin were used for the selection of transformants. The Pichia pastoris cells were grown in BMGY medium (1% yeast extract, 2% peptone, 1% glycerol, 1.34% yeast nitrogen base and 0.1 M potassium phosphate, pH 6.0) and BMMY medium (1% yeast extract, 2% peptone, 0.5% methanol, 1.34% yeast nitrogen base and 0.1 M potassium phosphate, pH 6.0) for induction. 165 -melittin. A DNA insert encoding melittin was prepared via artificial synthesis. A linker containing (GGGGS) 4 , EcoRI, ApaI, AccI and XbaI sequences were appended when the synthetic fragment was designed. Then, the melittin DNA fragment was digested with EcoRI and XbaI and ligated into a linearized pPICZαC vector to generate the plasmid pPICZαC/melittin.
Construction of expression vector containing pPICZαC/ VEGF
To clone the VEGF 165 gene, reverse-transcription polymerase chain reaction (RT-PCR) was performed with the primers 5'-ATT CTC GAG AAG AGA GCA CCC ATG GCA GAA GGA G-3' (forward) and 5'-GTA GAA TTC CCG CCT CGG CTT GTC ACA TTT TTA-3' (reverse), and total RNA extracted from human hepatoma (HepG2) cells served as the template. Following digestion with XhoI and EcoRI, the PCR fragment was cloned into pPICZαC/melittin and treated with the same endonucleases to generate the recombinant eukaryotic expression plasmid pPICZαC/VEGF 165 -melittin. The recombinant plasmid was confirmed by restriction analysis and sequencing.
Transformation and screening of recombinant strains.
Recombinant plasmid DNA was linearized with SacI and then transformed into Pichia pastoris X-33 by electroporation using a MicroPulser (Bio-Rad Laboratories, Hercules, CA, USA) following the pPICZαC vector manual. The yeast strains transformed with empty vector pPICZαC plasmid served as a negative control. The cells were spread on YPD plates containing Zeocin at 100, 250, 500 and 1,000 mg/ml and incubated at 28˚C. Colonies appeared after 2-3 days of incubation at 28˚C. The inserted foreign gene in the genomic DNA of transformants were detected by PCR assay using the primers mentioned above. Thirty cycles of PCR were performed with incubations for 30 sec at 94˚C, 30 sec at 55˚C and 1.5 min at 72˚C.
Optimized expression of the fusion protein in P. pastoris.
To confirm the optimal expression conditions for the fusion protein, various culture parameters, including induction time-points and pH values (pH 3.0-7.0 with 0.5 pH intervals), were evaluated. The processes were the same as above. At specific intervals, 0.5 ml cell suspensions were removed and then substituted with the same volume of fresh medium. The cell culture supernatant was tested by ELISA assays. 165 -melittin. VEGF 165 -melittin production was scaled up in 2 l BMGY medium based on the process introduced in the Invitrogen manual (19) . Transformants were cultured at 28˚C (pH 6.0) until the culture reached OD 600 =2.0-6.0, the cells were harvested by centrifugation, redissolved in 2 l BMMY medium, and cultured at 28˚C with oscillation for 72 h. The fermentation broth was supplemented every 24 h with 10 ml methanol to maintain the induced control.
Purification of VEGF
Fermentation supernatant was collected by filtration (0.45 µm) after harvesting by centrifugation at 12,000 r/min for 15 min. A Ni 2+ NTA column (GE Healthcare, Piscataway, NJ, USA) was equilibrated in binding buffer (20 mM Na 3 PO 4 ·12 H 2 O, pH 7.4, 0.5 M NaCl and 30 mM imidazole).
The supernatant was diluted 3-fold with binding buffer and loaded onto a Ni 2+ NTA column at a speed of 0.5 ml/min. Then, the column was washed with the same buffer at a rate of 1.0 ml/min to eliminate unbound proteins. Bound protein was then eluted from the column with 20 mM Na 3 PO 4 ·12 H 2 O, pH 7.4, 0.5 M NaCl and 0.2 M imidazole at a rate of 0.8 ml/min. Eluted protein was then transferred to storage buffer (1X PBS) by chromatography using a Thermo Scientific Zeba desalting column (Thermo Fisher Scientific, Waltham, MA USA).
Protein assay. The protein concentrations of the samples were measured using the Bradford assay with bovine serum albumin as a standard.
Enzyme-linked immunosorbent assay. Individual wells of ELISA plates (Costar) were coated with fusion toxin sample supernatants and coating buffer (Na 2 CO 3 -NaHCO 3 , pH 9.6, dilution: 2 µg/100 µl) overnight at 4˚C. The plates were blocked with 2% BSA in TPBS (PBS 1 , 0.1% Tween-20, pH 7.2) and incubated for 2 h at room temperature. The primary antibody against rabbit was used at 1:1,000 and precoated for 2 h at 37˚C. After several washes with TPBS, the plates were incubated with goat anti-rabbit IgG conjugated to HRP (1:2,000 dilutions at blocking buffer) for 2 h. The color reaction was implemented with OPD zymolyte containing 0.02% H 2 O 2 , and the plates were incubated for 15 min at room temperature in the dark. Then, 50 µl of H 2 SO 4 solution (2 M) was used to stop the reaction. Absorbance values at 490 nm were read using an ELX800 microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA). After adding stop solution, plate reads were completed within 2 h.
SDS-PAGE and western blot assays.
Cell lysates were separated by SDS-PAGE in 10% gels and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore) using a semi-dry electroblotting apparatus (Bio-Rad Laboratories) at 200 mA for 1 h in Towbin transfer buffer (25 mM Tris and 192 mm glycine). The membrane was blocked with 2% BSA for 1.5 h at room temperature. Then, the membrane was incubated with primary antibodies against rabbit for 12 h. After washing, the membrane was incubated with a goat anti-rabbit IgG antibody conjugated to HRP (Weijia, Shaanxi, China) that was diluted 1:250. The bound antibody was developed with 3,30-diaminobenzidine (DAB).
N-terminal amino acid sequence and mass spectrometric analyses. The N-terminal amino acid sequence of the VEGF 165 -melittin fusion protein was determined by automated Edman degradation, which was performed with a model protein sequencer-491 (Applied Biosystems, Foster City, CA, USA). The purified protein was adsorbed onto a PVDF membrane (ProSorb) and sequenced using established protocols. Mass spectrometric analysis of VEGF 165 -melittin was performed with an autoflex speed MALDI-TOF/TOF MS (Brucker Daltonics, Billerica, MA, USA).
Reverse transcription-polymerase chain reaction. Total cellular RNA was extracted from cell cultures using the RNAiso reagent (Takara, Tokyo, Japan) according to the manufacturer's protocol. RNA concentration was detected using a BioPhotometer (Eppendorf Scientific, Hamburg, Germany). Reverse transcription of total RNA primed with an oligo(dT) oligonucleotide was done with M-MLV reverse transcriptase (Promega, Mannheim, Germany) according to the instructions of the manufacturer. First-strand complementary DNA was amplified using Takara Ex Taq (Takara).
The primers for the respective genes were designed as follows: VEGF, 5'-GCA CCC ATG GCA GAA GGA-3' (forward) and 5'-TTC TGT ATC AGT CTT TCC-3' (reverse); VEGFR-1, 5'-GAA GGC ATG AGG ATG AGA-3' (forward) and 5'-CAG GCT CAT GAA CTT GAA-3' (reverse); KDR/VEGFR-2, 5'-CAT GTA CGG TCT ATG CCA-3' (forward) and 5'-CGT TGG CGC ACT CTT CCT-3' (reverse); and β-actin, 5'-TTC CTG GGC ATG GAG TCC-3' (forward) and 5'-CGC CTA GAA GCA TTT GCG-3' (reverse). RT-PCR products were analyzed by electrophoresis on a 1% agarose gel.
Cytotoxicity assay. Cells were seeded in 96-well plates at 5-10x10 4 cells/well. Cells were then starved with phenol red-free Dulbecco's modified Eagle's medium plus 1% dialyzed fetal calf serum (A15-107; PAA Laboratories, Dartmouth, MA, USA) for 24 h. The experiment included six VEGF 165 -melittin fusion protein groups (0, 0.8, 1.6, 3.2, 6.4 and 12.8 µg/ml). Human primary embryonic kidney cells (n=293) were used for control. Cell growth was induced by the fusion toxin for 48 h and then measured with the MTT assay. Absorbance at 570 nm was detected with a reference at 630 nm serving as a blank. The influence of the fusion toxin on cell activity was evaluated and compared with control. The control cells were set to 100% activity. The mean value of 5 wells was counted, and triplicates were used in each experiment.
To test VEGFR-mediated effects of VEGF 165 -melittin fusion protein on the proliferation and viability of human cancer cells, HepG-2 cells was used for subsequent studies. HepG-2 cells were cultured as described above. Five experimental groups were designed and HepG-2 untreated was the control group. 165 -melittin on hepatocellular carcinoma and pancreatic cancer xenografts in nude mice. After hypodermic injection of 2.5x10 7 HepG-2 or 5x10 6 AsPC-1 cells in BALB/c athymic nude mice, initial tumors were observed on day 21. Afterward, all mice in the experimental groups were intravenously injected with 0.2 mg VEGF 165 -melittin daily for 28 days, and PBS was used as a control. The subcutaneous tumor parameters were measured every day, including the length, width and height. The tumor volume (mm 3 ) was estimated according to the equation a 2 b/2, where a is the short diameter (mm) and b is the long diameter (mm). The tumor weights were measured after the mice were sacrificed. The tumor samples were maintained in formalin, and an assessment of mortality was performed.
Inhibitory effects of VEGF

Results
VEGF 165 -melittin expression and optimization. A plasmid was created to express the VEGF 165 fragment fused to melittin to generate a 25 kD VEGF 165 -melittin fusion toxin. The structure of the details of VEGF 165 -melittin is shown in Fig. 1A . pPICZαC/melittin is based on the Pichia pastoris expression vector pPICZαC. This vector was used to express the VEGF 165 -melittin fusion protein, which is composed of the melittin fragment cut from the ApaI and XbaI sites following the VEGF 165 fragment. A linker, (GGGGS) 4 , was synthesized for spatial configuration of the fusion toxin. The VEGF 165 sequence was amplified and inserted into the pPICZαC/melittin expression vector to create pPICZαC/VEGF 165 -melittin. Sequence analysis of the plasmid DNA was used to confirm integration in positive colonies.
After electroporation with SacI-linearized pPICZαC/ VEGF 165 -melittin, 90% of transformants were Mut + . PCR analysis of genomic DNA demonstrated that the gene of interest was integrated into the stable transformants, and no similar bands were observed for negative control samples.
The positive transformants were germinated in BMGY medium and induced in BMMY medium at 28˚C for 7 days. The volume of the culture medium was 10 ml. After 3 days, the culture supernatants were analyzed by SDS-PAGE. The results indicated that the molecular weight of VEGF 165 -melittin was consistent with the predicted size of 25 kDa (Fig. 1B ).
Transformants expressing a high level of fusion protein were selected, and one was chosen for the scaling up. Based on analysis of optimized expression conditions, the parameters used were as follows: pH: 6.0, induction time-point: 72 h, and final methanol concentration: 0.5% (v/v) ( Fig. 1C and D) . 165 -melit tin fermentation a n d purif ication. VEGF 165 -melittin supernatant was purified by Ni 2+ affinity chromatography and Thermo Scientific Zeba desalting column chromatography. Following these processes, ~160 mg pure recombinant protein was obtained from 2 l fermentation liquor. SDS-PAGE analysis demonstrated that the purity of VEGF 165 -melittin was ~95% ( Fig. 2A) . At every step of purification, the recovery, purity and yield of the fusion toxin were estimated as shown in Table I .
V E GF
Western blot assays were used to preliminarily evaluate the purified recombinant protein. The identity of VEGF 165 -melittin was confirmed by immunoreactivity with a rabbit anti-human VEGF 165 polyclonal antibody (Fig. 2B) . The results were consistent with our expectations. No band was observed in lane 1, which contains the supernatant of the X33 pPICZαC transformant.
Molecular weight and N-terminal sequencing analyses.
To verify the molecular weight and integrity of the recombinant protein, mass spectrometry was performed using purified VEGF 165 -melittin. The expected molecular mass VEGF 165 -melittin is 221 amino acids, and it primarily exists in solution as a homodimer due to a disulfide linkage in the linker. The results of the molecular weight analysis of the fusion toxin are shown in Fig. 3 , and they are in accordance with our previous results, indicating that the purified recombinant toxin is the expected VEGF 165 -melittin protein.
According to N-terminal sequencing analysis, the first 15 amino acids of the purified peptide were A P M A E G G G Q N H H E V V. These were consistent with the N-terminal sequence of VEGF 165 -melittin, thus indicating successful expression and purification of this protein.
Cytotoxicity assay. The effects of VEGF 165 -melittin on the proliferation and viability of human hepatocellular carcinoma cell lines (HepG-2 and MHCC97-H), human pancreatic adenocarcinoma cell lines AsPC-1 and human primary embryonic kidney cells 293 were studied for a 72-h period. The fusion protein was applied to the cells at seven different final concentrations. Fig. 4 shows the proliferation and viability changes that occurred during treatment. Cell counts and an MTT-assay indicated that the fusion toxin influenced the proliferation of HepG-2 and MHCC97-H cells more significantly than that of AsPC-1 cells. The proliferation of the HepG-2 cells significantly decreased by 55% in an MTT assay (P<0.01). However, an effect of the fusion toxin on the viability of 293 cells was not observed, even at the highest VEGF 165 -melittin dose.
To further assess the mediation effects between VEGF 165 -melittin and VEGFR inhibition, human hepatocellular carcinoma cells HepG-2 were incubated with VEGF 165 -melittin or melittin for 48 h in the presence or absence of 0.5 µg/ml anti-VEGF antibody. Fig. 5 shows the proliferation of the HepG-2 cells significantly decreased when melittin or VEGF 165 -melittin was added (P<0.01). However, in VEGF 165 -melittin groups, the inhibitory activity was not observed after incubated with the anti-VEGF antibody. This sensitivity of HepG-2 might be mediated by VEGFR present on HepG-2 cells, since 293 cells without known VEGF receptors were not affected by VEGF 165 -melittin at high concentrations (Fig. 4) .
Presence of VEGFR appears to be necessary for induction of HepG-2 cell death by VEGF 165 -melittin.
VEGF 165 -melittin-mediated tumor growth inhibition in vivo.
In the HepG-2 xenograft nude mouse model, the average tumor volume in VEGF 165 -melittin mice was 843 mm 3 , and it was 1,769 mm 3 in control mice (Fig. 6A) . Therefore, the inhibitory rate of the average tumor volume was 52.3%. Twenty-eight days after treatment with the fusion toxin, the survival was 100% for VEGF 165 -melittin mice and 60% for control mice (Fig. 6B) . In the AsPC-1 xenograft nude mouse model, inhibition of the average tumor volume in the experimental group was 34.4% as compared with the control group. Significant VEGF 165 -melittin-mediated inhibition of tumor growth was demonstrated. Based on these results, it was obvious that there were stronger effects in HepG-2 compared with AsPC-1 cells, which suggests that the high expression level of VEGFR-2 in HepG-2 might mediate this influence.
Specific toxicity of VEGF 165 -melittin targeting VEGFR-2.
Expression of VEGF, VEGFR-1 and KDR/VEGFR-2 in HepG-2 and MHCC97-H cells as well as AsPC-1 cells were determined with RT-PCR and western blot assays ( Fig. 7A  and B ). All three cell lines exhibited VEGF. MHCC-97H cells were positive for VEGFR-1 and KDR/VEGFR-2. KDR/VEGFR-2 was expressed in HepG-2 and VEGFR1 was expressed in AsPC-1.
Furthermore, KDR/VEGFR-2 was overexpressed in 293 cells to evaluate the specific targeting of fusion protein (Fig. 8A) . The effect of VEGF 165 -melittin on the proliferation and viability of 293 cells, 293 transfected with pCMVp-NEO-BAN/KDR plasmid (293/KDR) and HepG-2 cells was studied. The 293 cells transfected with pCMVp-NEO-BAN empty plasmid (293/pCMV) were used as control. In targeted cells, the cytotoxicity of VEGF 165 -melittin was strongly dependent on the VEGFR-2 density. Fig. 8B shows proliferation and viability changes using the MTT assay. Statistical analysis. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) 13.0 software. Data are presented as the means ± SD. Statistical significance was determined by one-way analysis of variance or the t-test. P-values <0.05 were considered to be statistically signifi cant.
Discussion
It is well known that tumor cell-derived VEGF is a key factor that acts on endothelial cells to promote angiogenesis, tumor growth and metastasis. Targeting proangiogenic mediators such as VEGF/VEGFR has emerged as a promising anticancer treatment strategy. In particular, VEGF fusion proteins have become an important aspect in novel cancer treatment strategies (20) . In the present study, we constructed a protein containing VEGF 165 fused to melittin (VEGF 165 -melittin). Successful expression of active VEGF 165 -melittin was achieved in Pichia pastoris with yields >80 mg/l. N-terminal sequencing and mass spectrometric analysis verified that the fusion toxin was expressed and purified as expected. MTT and xenografts assays demonstrated that VEGF 165 -melittin inhibited tumor growth in vivo and in vitro.
Among the identified proangiogenic regulators, VEGF, particularly VEGF-A and its two tyrosine kinase receptors, fms-like tyrosine kinase receptor (Flt1 and VEGFR-1) and kinase insert domain-containing receptor (KDR/FLK1 and VEGFR-2), have been identified as key mediators of the regulation of pathologic blood vessel growth and maintenance (21) . In our results, VEGF 165 -melittin was more effective in HepG-2 than MHCC97-H cells. This diversity may be caused by differences in the VEGFR-1 and VEGFR-2 proteins expressed in HepG-2 and MHCC97-H cells. In subsequent studies, the expression of VEGF and the VEGF receptors (VEGFR-1 and VEGFR-2) was evaluated in HepG-2 and MHCC97-H cells by RT-PCR and western blot assays. Compared with the results we reported here, the VEGF 165 -melittin fusion toxin should be selective in targeting tumor cells that overexpress VEGFR-2. We hypothesize that the enhanced efficacy of VEGF fusion toxin may be due to the overexpression of VEGFR-2 in growing cells. Subsequently, 293 human primary embryonic kidney cells (293/KDR) overexpressing VEGFR-2 was constructed in our laboratory. VEGF 165 -melittin inhibited growth of 293/ KDR cells at a dose of 6.4 µg/ml. These effects were mediated by VEGFR-2, since the parental 293 cells lacking VEGFR-2 were not inhibited by fusion protein.
Melittin is a main component of bee venom. It is a small peptide with a linear structure composed of 26 amino acids (22) . Bee venom has a wide range of effects including antibacterial, antiviral and anti-inflammatory effects; thus, it has been extensively used in the field of traditional medicine including treatments for back pain, rheumatism and skin diseases (23, 24) . Furthermore, it has been shown that bee venom and/or melittin have inhibitory effects on the tumor growth of cervical, prostate, renal, breast, ovarian and liver tumor cells (10, 25, 26) . The results of our research are in accordance with previous studies demonstrating the suppression of melittin on the growth of human hepatic carcinoma cell lines (11, 27) . Additionally, the fusion toxin VEGF 165 -melittin inhibited the proliferation of human hepatocellular carcinoma cell lines (HepG-2 and MHCC97-H) in a concentration-dependent manner. The most effective inhibitory concentration of VEGF 165 -melittin was 6.4 µg/ml, resulting in an inhibition ratio of 52.3%. The remarkable suppressive effects on cell proliferation were observed after 48 h in the experimental group. The present study indicated that the fusion toxin directly inhibits the growth of hepG-2 human hepatocellular carcinoma cells in vitro and in vivo. In follow-up experiments, more studies will be designed to detect the antitumor activity and mechanism of this fusion protein.
As a lower eukaryote, Pichia pastoris was identified as a suitable expression system for various recombinant proteins that retains biological activity with high quantity yields, and it also offers the benefits of E. coli (cost-effective and easy scale-up). In addition, the advantages of expression in a eukaryotic system include proper protein processing, folding and post-translational modifications (28, 29) . In addition, Pichia pastoris does not secrete large amounts of intrinsic proteins, resulting in the easy isolation of foreign proteins. In the present study, VEGF 165 -melittin production was performed in a 2-liter fermentor, with yields >80 mg/l. The successful expression and purification of the recombinant fusion toxin VEGF 165 -melittin and its activity in human hepatocellular carcinoma cells demonstrates that the fusion protein has the potential to be used as a novel cancer treatment strategy. This is the first report to describe the secretory expression of a human vascular endothelial growth factor fused to melittin in Pichia pastoris.
